1. Medtech Insight

Hard Truths About Mistruths: US FDA’s Califf Switching Gears On Misinformation Fight

 
• By Derrick Gingery

Fighting misinformation likely will not be successful, the FDA commissioner conceded, but stakeholders should join the campaign to increase the dissemination of truthful information.

Robert Califf at the Milken Institute Future of Health Summit
FDA Commissioner Robert Califf addressed many subjects during the Milken Institute Future of Health Summit. • Source: Derrick Gingery

{Editor's Note: This article originally appeared in Pink Sheet, Medtech Insight's sister publication covering regulation and policy in the pharmaceutical industry.]

Robert Califf has resigned himself to the fact that the US Food and Drug Administration’s strategy of waging a full-frontal assault on misinformation has to change.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.